Technology >> Analyst Interviews >> September 11, 2013
Echo He, M.D., Ph.D., is a Senior Vice President and and Senior Analyst at Maxim Group LLC. Prior to joining Maxim Group LLC in 2009, she was a Director and an Equity Analyst at Oppenheimer & Co. Inc. Prior to Oppenheimer & Co. Inc., Dr. He served as a Vice President and an Analyst at CRT Capital Group, where she conducted equity and credit analysis. Earlier in her career, she was a Research Scientist at the National Institutes of Health, where she participated in the Human Genome Project aimed at interpreting diseases and their risks by genetic patterns. Prior to the NIH, she worked as a postdoctoral research fellow at Indiana University Medical Center, where she investigated gene therapy for pulmonary diseases and potential drug targets of human HIV infected cells. Dr. He received an M.D. in clinical medicine from Beijing University Medical School, a Ph.D. in medical sciences from the Medical College of Ohio and an MBA from the University of Chicago Booth School of Business. Profile
TWST: What has been the impact so far for Sina of the Weibo-Alibaba collaboration, and what do you expect the impact to be going forward?
Dr. He: I would say Sina (SINA),